The Coronavirus Treatment Acceleration Program launched by the FDA in response to Covid-19 is a Supercharged Fast-Track Approval process that reduces the Fast-Track Approval timeline from 18 months to as soon as possible in order to get treatment to the patients as fast as possible.
A vaccine traditionally takes 7-8 years to develop from the laboratory tables to the patient. The Covid-19 pandemic is inducing a rush of clinical trials for existing drugs and biologics to see if they can be potentially used against the virus, as well as initiating novel approaches, including mRNA, DNA vaccine, and vectors to be tested through clinical trials.
“The list of biopharmaceutical companies rapidly developing vaccines is growing in response to the novel Coronavirus (Covid-19) pandemic. Moderna Therapeutics has a messenger RNA (mRNA) in Phase I trials, Inovio Pharmaceuticals’ DNA vaccine entered human trials the first week of April, while others including Novovax, which is developing a vaccine based on its recombinant protein nanoparticle platform.”
Innovators are doing their part, and so is the FDA. Breakthrough Therapy Designation or Fast-Track Approval was implemented by the FDA for accelerating treatment development for serious conditions such as the Coronavirus pandemic. This pandemic prompted the FDA to further supercharge the process by creating the Coronavirus Treatment Acceleration Program (CTAP). The FDA intends to use all of the regulatory flexibility granted to it by Congress to ensure the most efficient and timely development of vaccines to fight Covid-19.
- The FDA will generally respond within a day to requests from developers and scientists to develop or evaluate new drug and biologic therapies.
- Provide ultra-rapid, interactive input on most development plans.
- Provide ultra-rapid protocol review – within 24 hours of submission, in some cases.
- Complete review of single-patient expanded access requests around-the-clock, generally within 3 hours.
Supply Chain challenges for Covid-19 vaccines and therapies
The vaccines or treatments aimed at treating high patient populations globally to control a pandemic will require millions if not billions of doses. Most of the leading Covid-19 vaccine candidates are using novel approaches, including mRNA, DNA vaccine, and vectors that are highly sensitive to environmental hazards occurring during transportation such as temperature, shock, and vibration.
Is your current supply chain ready for the volume, global distribution, and speed of new therapy approvals? Early implementors will rise to the challenge.
Not ready to address supply chain challenges yet? Line up your Supply Chain experts for when you are ready.
Modality Solutions has successfully worked with clinical trial supply chain issues for the Ebola vaccine, and we have the testing capabilities to evaluate the effects of environmental hazards throughout the supply chain. We also have the expertise of integrating existing or creating new supply chain protocols for therapies developed to treat the Coronavirus.